CCHT(SZ:000661) Xin Lang Cai Jing·2025-08-29 15:31Core Viewpoint - Changchun High-tech reported a decline in revenue and net profit for the first half of 2025, indicating potential challenges in its business performance [1][2]. Financial Performance - The company's revenue for the first half of 2025 was 6.603 billion yuan, a year-on-year decrease of 0.54% [1]. - The net profit attributable to shareholders was 983 million yuan, down 42.85% year-on-year [1]. - The basic earnings per share were 2.44 yuan [2]. - The gross profit margin for the first half of 2025 was 83.35%, a decrease of 1.27 percentage points year-on-year [2]. - The net profit margin was 14.11%, down 12.93 percentage points compared to the same period last year [2]. Cost and Expenses - Total operating expenses for the first half of 2025 were 4.256 billion yuan, an increase of 943 million yuan year-on-year [2]. - The expense ratio was 64.46%, up 14.55 percentage points from the previous year [2]. - Sales expenses increased by 23.43%, management expenses by 31.26%, R&D expenses by 30.22%, and financial expenses surged by 85.44% [2]. Shareholder Information - As of the end of the first half of 2025, the total number of shareholders was 109,100, a decrease of 16,000 or 12.78% from the previous quarter [2]. - The average market value per shareholder increased from 318,900 yuan to 370,800 yuan, a growth of 16.28% [2]. Company Overview - Changchun High-tech, established on June 10, 1993, and listed on December 18, 1996, is located in Changchun, Jilin Province [3]. - The company primarily engages in the research, production, and sales of biopharmaceuticals and traditional Chinese medicine, with real estate development and property management as supplementary businesses [3]. - The revenue composition includes 88.40% from biopharmaceuticals, 5.66% from traditional Chinese medicine, 5.61% from real estate, and 0.32% from services [3].